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Ovarian cancer is the deadliest gynecologic malignancy in the
United States, with an estimated 22,240 new cases and 14,030
deaths in 2013.1 In the 1970s, women with ovarian cancer had an
average 5-year overall survival of 36%.1 Modest improvement has
been made in the past 40 years, with the average 5-year survival now
reaching 43%.1 Several advances have led to better outcomes. These
include more uniform efforts to render ovarian cancer patients
optimally debulked, the introduction of platinum and taxane agents
into frontline treatment, the adoption of dose-dense and intraperi-
toneal chemotherapy strategies, and the development of other active
agents for the treatment of ovarian cancer.
Discussion
Evolution of the Deﬁnition of “Optimally Debulked”
to  1 cm Residual Disease
Abundant evidence suggests that optimal cytoreduction is the key
to achieving the best outcome in ovarian cancer. The controversy
lies in the deﬁnition of “optimal cytoreduction” and the strategy by
which it can be accomplished. As early as 1975, it was recognized
that survival was inversely related to residual tumor size; patients
with residual tumor deposits > 1.5 cm had a poorer prognosis
compared with those with < 1.5 cm in residual disease.2 With
improvements in surgical technique, critical care, and postoperative
support, more aggressive surgery was possible, and the deﬁnition of
“optimal cytoreduction” evolved.
In 1994, Hoskins and colleagues performed an ancillary study
of Gynecologic Oncology Group (GOG) study 97 and found that
women who had residual tumor deposits < 1 cm had improved
survival compared with women with a larger disease burden, setting
the current deﬁned standard for “optimally debulked” (“optimal”)
as < 1 cm residual disease.3 Chi and colleagues conﬁrmed this inDepartment of Obstetrics and Gynecology, The University of Alabama at Birmingham,
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http://dx.doi.org/10.1016/j.cogc.2013.12.0012001, publishing their experience of 282 patients with advanced-
stage ovarian cancer.4 Among 18 factors evaluated in their multi-
variate analysis, only age, ascites, and residual disease were deter-
mined to correlate with prognosis. Ovarian cancer patients with
stage III disease who underwent an optimal debulking had a median
survival of 56 months compared with 31 months in women with
gross residual disease. There was no difference in median survival in
women with 1 to 2 cm of residual disease compared with those with
> 2 cm of residual disease. Of note, only 25% of their study
population had an optimal cytoreduction, which the authors
partially attributed to the nonuniform deﬁnition of “optimal.” More
than a decade later, this confusion continues to pose an issue.
Evidence for Deﬁning “Optimally Debulked” as No
Residual Disease
Aggressive cytoreduction to achieve no gross residual disease
(NRD) was a natural extrapolation from data that suggested an
inverse linear relationship between survival and residual disease.
Eisenkop et al. reported their experience with attempted complete
cytoreduction in 163 patients.5 They achieved NRD in 85.3% (139
of 163) of their patients, although this was tempered by fairly high
surgical morbidity. Survival signiﬁcantly correlated with cytor-
eduction, with a hazard ratio of 2.14 in patients who were not
disease-free at the completion of primary surgery. Bristow and
colleagues performed a meta-analysis of the available cytoreduction
evidence in 2002.6 Their results showed that for every 10% increase
in maximal cytoreduction, the median survival increased by 5.5%.
Patient cohorts with a  25% maximal cytoreduction had a median
survival of 22.7 months, whereas cohorts with a > 75% maximal
cytoreduction had a 50% longer median survival of 33.9 months.
Further evidence that patients who are visibly disease-free at the
completion of primary surgery have a signiﬁcantly better overall
survival than patients who have any macroscopic disease comes from
GOG trials 104 and 172.7,8 Both trials demonstrated the overall
survival superiority of intraperitoneal (IP) chemotherapy in pri-
marily optimally debulked patients. Subanalysis of those patients
who underwent cytoreduction to only microscopic disease showed
an even more pronounced survival beneﬁt. Impressively, patients in
GOG 172 who had no residual disease and received IP therapy had
not reached a median survival at the time of publication in 2006,Clinical Ovarian and Other Gynecologic Cancer December 2012 - 45
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46 -5 years after the trial closed to accrual.8 Combining a superior
chemotherapy regimen with maximal cytoreduction likely has the
greatest impact on overall survival.
Role of Neoadjuvant Chemotherapy in Achieving Optimal
Debulking
There are ovarian cancer patients who cannot tolerate aggressive
primary surgery or who are not able to be optimally debulked, no
matter how aggressive the surgeon may be. Ovarian cancer patients
with signiﬁcant comorbidities may fare worse with extensive sur-
gery. Those who have signiﬁcant pulmonary or intrahepatic disease
burdens pose a surgical challenge. Bristow et al. and Winter et al.
separately published series on patients with stage IV ovarian cancer
and found that women with extensive suboptimally debulked he-
patic metastases did worse than women who had complete resection
of all disease.9,10 Winter et al. went as far to suggest that ultraradical
surgery should only be considered in selective ovarian cancer pa-
tients “in whom microscopic residual disease is possible.”10
Neoadjuvant chemotherapy has been suggested as an alternative
to surgery for those patients who have signiﬁcant medical comor-
bidities or in whom a reasonable attempt at primary complete
cytoreduction is not feasible. Two large multinational trials have
examined the efﬁcacy of neoadjuvant chemotherapy followed by
interval debulking surgery (IDS) in patients with advanced-stage
ovarian cancer. The European Organization for Research and
Treatment of Cancer (EORTC) trial compared the effect of 6 cycles
of neoadjuvant cyclophosphamide and cisplatin to 3 cycles of
neoadjuvant chemotherapy followed by IDS and an additional 3
cycles.11 Women who had small-volume disease prior to IDS had a
similar overall survival to women who had an optimal IDS. Both of
these groups had a superior overall survival compared with women
who had a suboptimal IDS or who did not have surgery at all.
Vergote and colleagues published a randomized trial comparing
primary debulking surgery and platinum-based neoadjuvant therapy
followed by IDS and found that survival was equivalent in
both groups.12 A common criticism of both of these trials is that
patients were not necessarily treated by gynecologic oncologists; it is
possible that women did not undergo primary maximal
surgical effort, which could account for the nonsuperiority of initial
cytoreduction. In a 2009 meta-analysis of neoadjuvant studies,
Kang and colleagues reported that while it did not improve overall
survival, neoadjuvant chemotherapy decreased the odds of a sub-
optimal cytoreduction.13 Taken together, this data suggests that
maximal surgical effort should be primarily exerted if the patient can
be rendered disease-free. In the face of apparently unresectable
disease, however, patients may beneﬁt from neoadjuvant chemo-
therapy followed by an aggressive cytoreduction with no residual
disease being the goal.
Deﬁning a New Paradigm for Achieving NRD-Deﬁned
Optimal Debulking
The optimal paradigm of treating women with newly diagnosed
advanced-stage ovarian cancer remains elusive. However, certain
tenets are becoming clear. It is apparent that women whose disease
burden can be reduced to microscopic disease have a signiﬁcant
survival advantage. How that is best achieved is still controversial.
Women who present with small-volume disease fare best, as theirClinical Ovarian and Other Gynecologic Cancer December 2012surgeries are less complicated and complete resection is more
frequently achieved. In women with large-volume disease, complete
resection is less feasible. Could NRD be obtained in women
with initially unresectable disease with neoadjuvant chemotherapy
followed by an interval attempt at cytoreduction? Available evidence
suggests that this may indeed be the case.
If NRD is the ultimate goal, then does it matter how it is ach-
ieved? In patients who are too sick to undergo aggressive surgery and
the morbidity it entails or who appear to have disease not amenable
to being optimally cytoreduced, neoadjuvant treatment (whether
conventional or a dose-dense paclitaxel regimen) should be given to
reduce tumor burden while the patient’s performance status
improves. At the time of IDS, if NRD is achieved, why not denote
this time as “point zero” and treat the patient as someone who
achieved NRD at primary surgery? This could conceivably entail
placement of an IP catheter with plans to treat with up to 6 cycles
of intraperitoneal chemotherapy, an approach demonstrated to be
effective in a recent phase II trial.14 Alternatively, a dose-dense
paclitaxel regimen the patient may have received prior to surgery
could be continued. Achieving NRD, regardless of how a patient gets
there, is of paramount importance in the treatment of this disease.
Such an approach may result in potentially more therapy. That said,
the argument could be made that a patient who was suboptimally
debulked was going to receive more than 6 cycles of standard
chemotherapy treatment to control her disease regardless, and the
survival beneﬁts of an NRD strategy have been clearly demonstrated.
Conclusion
The landscape of health care is rapidly changing. Resources are
increasingly limited and rational quality indicators need to be
deﬁned for the management of patients with ovarian cancer. If
NRD is the ideal therapeutic goal, it may be that neoadjuvant
chemotherapy followed by IDS in patients with large-volume
disease is a way to improve quality while containing costs. The
ideal neoadjuvant and adjuvant regimens in ovarian cancer are still
being deﬁned, and emerging data regarding dose-dense paclitaxel
therapy and biologics such as bevacizumab need to be incorporated
into these paradigms. Research deﬁning which treatments are cost-
effective while maximizing patient outcomes is desperately needed.
Ovarian cancer patients deserve the best chance at optimizing their
survival. The ﬁrst step to providing this is achieving optimal cytor-
eduction and preferably eradicating all visible disease. Whether it is
best achieved through a primarily surgical approach or a combined
neoadjuvant chemotherapy/IDS depends on the patient. As the
biology of ovarian cancer is better elucidated, we will be better able to
choose which patients will beneﬁt most from each option.
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